Frontlight ResearchEarly access
Active, not recruitingPhase 3
Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration
Key facts
- Who runs it
- Kissei Pharmaceutical Co., Ltd.
- Where
- Japan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 142 people, planned
- Started
- 15 Aug 2025
- Expected to end
- 31 Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- KPS-0373
- Placebo
- Record updated
- 4 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Japanese SCD patients with mild to moderate ataxia
Who cannot take part
- Patients with secondary ataxia
- Patients with clinically significant hepatic, renal, or cardiovascular dysfunction
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of KPS-0373 given once daily after breakfast in 142 patients with spinocerebellar degeneration . This study consists of the 4-week screening period, 24-week treatment period, and 4-week follow-up period.
The 2 groups in the trial
- KPS-0373 groupTreatment being tested
One KPS-0373 2.4 mg tablet is orally administered once daily after breakfast.
Treatment: KPS-0373
- Placebo groupPlacebo, for comparison
One placebo tablet is orally administered once daily after breakfast.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase III Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration
- Record updated
- 4 September 2026